Celadon Pharmaceuticals (LSE:CEL) Long-Term Debt : €0.02 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Long-Term Debt?

Celadon Pharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2023 was €0.02 Mil.

Celadon Pharmaceuticals's quarterly Long-Term Debt declined from Dec. 2022 (€0.03 Mil) to Jun. 2023 (€0.02 Mil) and declined from Jun. 2023 (€0.02 Mil) to Dec. 2023 (€0.02 Mil).

Celadon Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.03 Mil) but then declined from Dec. 2022 (€0.03 Mil) to Dec. 2023 (€0.02 Mil).

Celadon Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Celadon Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Long-Term Debt Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

0.05

0.03

0.02

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial			-	0.03	0.03	0.02	0.02

Celadon Pharmaceuticals (LSE:CEL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Celadon Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines